Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

AcademyQ&A

Q&A

Review Types and Protocols Q&A: Scoping Reviews, PRISMA-ScR, Protocol Registration and AWMF Guidelines

Twenty-eight short answers on the JBI scoping method, PRISMA-ScR items, where and when to register, rapid review reporting and AWMF guideline rules.

Dr. CharlieSenior Medical WriterPublishedReading time10 minutesSources18
  • Scoping review
  • PRISMA-ScR
  • AWMF

At a glanceQ&A

PRISMA-ScR
20 essential + 2 optional items
Scoping registration
OSF, INPLASY or published protocol
OSF embargo
Up to 4 years
AWMF validity
Max. 5 years; living: updated at least every 12 months

Explore scoping review servicesDiscuss your project

Quick answer

  • Choose a scoping review to map evidence and gaps, frame it with PCC and report it with the 22-item PRISMA-ScR checklist.
  • Register scoping review protocols on OSF or INPLASY or publish them; PROSPERO does not accept scoping reviews.
  • AWMF S3 guidelines combine a systematic evidence base with structured consensus and remain valid for a maximum of five years.

Overview

This page collects short, technical answers to common questions about scoping reviews, the PRISMA-ScR checklist, protocol registration, rapid reviews and German AWMF guideline rules. It is written for review teams, particularly in Germany, who need to pick the right review type and meet journal, registry and guideline-programme expectations.

Each topic links to further reading. If your only question is where to register a scoping review protocol, our shorter scoping review protocol registration Q&A covers that alone; this page adds the checklist, review-type and AWMF detail around it.

Table 1. Topics on this page and where to read more.

TopicQuestionsRead more
Scoping reviews (JBI method)1–6How to write a scoping review
PRISMA-ScR checklist7–12PRISMA-ScR checklist item by item
Protocol registration13–18PROSPERO vs OSF vs INPLASY
Rapid reviews19–21Rapid review support
AWMF guidelines22–28AWMF S3 guidelines and evidence reviews

For worked examples that apply these answers to realistic projects, see our review types and protocols case studies.

1. Scoping Reviews (JBI Method)

1. When should I choose a scoping review?

When the aim is to map the extent, range and nature of the evidence, clarify concepts or definitions, examine how research has been conducted, or identify knowledge gaps, rather than to answer a focused question about effectiveness or harm12. If you need a pooled effect estimate or a recommendation for practice, a systematic review is usually the better fit1.

2. What does PCC stand for?

Population, Concept and Context, the JBI framework for framing a scoping review question and its eligibility criteria23. Eligibility criteria should also state the types of evidence sources, languages and dates considered.

3. What is the JBI three-step search?

An initial limited search of at least two relevant databases to identify text words and index terms; a full search using all identified terms across all included databases and sources; and screening of the reference lists of included sources for additional material23.

4. What is data charting?

The scoping review term for data extraction: recording relevant information from each source on a charting form that is piloted and refined iteratively. Chart only items that answer the review question34.

5. Is critical appraisal required?

Generally not. JBI guidance states that scoping reviews do not usually appraise the methodological quality of included sources; if a team chooses to appraise, it should justify why, and results are typically used to describe, not exclude, sources23.

6. How are scoping review results presented?

Descriptively: tables, charts or evidence maps, accompanied by a narrative summary that relates the findings to the review question. Results should not be presented as evidence of effectiveness4. Our scoping review guide walks through each stage with an example.

Sources for this topic: Munn 2018; Peters 2020; JBI Manual 2024; Pollock 2023.

2. PRISMA-ScR Checklist

7. How many items does PRISMA-ScR contain?

22: 20 essential items and two optional items5. It was adapted from the PRISMA 2009 checklist, with five items removed and two made optional.

8. Which items are optional?

Item 12 (critical appraisal of individual sources of evidence) and item 16 (results of that appraisal)5.

9. What search detail is required?

Item 7 asks for all information sources with dates of coverage, contact with authors to identify additional sources, and the date the most recent search was executed. Item 8 asks for the full electronic search strategy for at least one database, including any limits used, so that it could be repeated5. Our PRISMA-S guide adds detail on search reporting.

10. Is a flow diagram required?

Not strictly. Item 14 asks for the numbers of sources screened, assessed for eligibility and included, with reasons for exclusion at each stage, ideally using a flow diagram5. There is no separate PRISMA-ScR flow template; authors usually adapt the PRISMA 2020 flow diagram6.

11. What reporting problems should I check for before submission?

Gaps worth checking include a missing protocol or registration statement (item 5), no full search strategy for at least one database (item 8), an incomplete source selection count (item 14), undeclared funding of the review or of included sources (item 22) and conclusions that read as effectiveness claims. Check each item against the manuscript section where it appears; our item-by-item PRISMA-ScR guide maps every item to its section.

12. Is PRISMA-ScR being updated?

Yes. An update is in development: a 2026 scoping review identified 37 candidate reporting items for a subsequent Delphi survey7. Until an updated checklist is published, the 2018 version remains the one to use.

Sources for this topic: Tricco 2018; Page 2021; Tricco 2026.

Planning a scoping review?

Pubrica’s scoping review team supports PCC question development, JBI-aligned protocols, OSF or INPLASY registration, searching, charting and PRISMA-ScR reporting. Review authors keep ownership of and accountability for the review, and no provider can guarantee acceptance or set journal timelines.

3. Protocol Registration

13. Can I register a scoping review in PROSPERO?

No. PROSPERO accepts systematic reviews, including rapid and umbrella reviews, with at least one outcome of direct relevance to health; it does not accept scoping reviews, mapping reviews or evidence maps8. The registry relaunched in March 2025 with more automated processing and easier searching for existing similar reviews9; check its current eligibility page before submitting.

14. Where can a scoping review protocol be registered?

Three common routes:

  • OSF Registries, using the Generalized Systematic Review Registration form, which covers scoping reviews1011.
  • INPLASY, which offers a dedicated scoping review form for a fee (US$20 per registration and US$9 per update as of June 2023; check the current fee)12.
  • A published protocol, for example in JBI Evidence Synthesis, structured with JBI protocol guidance13.

Our PROSPERO vs OSF vs INPLASY comparison sets out the workflow for each.

15. What identifier does OSF provide, and when?

A DOI with the 10.17605/OSF.IO prefix. DOIs are minted only for public registrations, so an embargoed registration receives its DOI when it becomes public11. After submission, project administrators have 48 hours to approve or cancel; otherwise the registration is approved automatically11.

16. Can an OSF registration be embargoed?

Yes, for up to four years from submission, after which it becomes public automatically11. Note that an embargoed protocol is not publicly verifiable until it is released, which matters if a journal asks for proof of prospective registration.

17. Which guideline structures a review protocol?

For a systematic review, PRISMA-P 2015 (17 items, 26 including sub-items)14. For a scoping review, use the JBI best-practice guidance and reporting items for scoping review protocols13.

18. When should registration happen?

Best practice for any review is to register before screening begins. PROSPERO’s published rules accepted a review only if data extraction had not been completed15; check PROSPERO’s current eligibility guidance before registering. OSF and INPLASY record the registration date, so readers can see whether registration was prospective; report any later amendments with reasons.

Sources for this topic: PROSPERO; CRD 2025; van den Akker 2023; OSF Support; Canellas 2023; Peters 2022; Moher 2015; Booth 2012.

4. Rapid Reviews

19. What is a rapid review?

A form of evidence synthesis that streamlines or omits some systematic review methods to produce evidence for decision-makers more quickly. Updated Cochrane rapid review methods guidance for reviews of effectiveness was published in 202416.

20. How should rapid review shortcuts be reported?

State and justify every streamlined step, such as fewer databases, date or language limits, or single-reviewer screening with verification by a second reviewer, and discuss how the shortcuts may affect the findings16. Agree the shortcuts with the people commissioning the review before starting.

21. Can a rapid review be registered?

Yes. PROSPERO accepts rapid reviews that meet its eligibility criteria, including a health-related outcome8. For help scoping a rapid review, see our rapid review service.

Sources for this topic: Garritty 2024; PROSPERO.

5. AWMF Guidelines

AWMF guidelines are recommendations of the German medical scientific societies, developed under the AWMF-Regelwerk; they are not statutory regulation17. Rules can change between Regelwerk versions, so check the current version before planning a guideline project.

22. What are the AWMF guideline classes?

Four classes17:

Table 2. AWMF guideline classes.

ClassSystematic evidence baseStructured consensus
S1No (expert group recommendations)No
S2kNoYes, representative group
S2eYes, systematic search and appraisalNo
S3YesYes, representative group

23. What do grades A, B and 0 mean?

A is a strong recommendation (“soll” / “soll nicht”), B a recommendation (“sollte” / “sollte nicht”) and 0 an open recommendation (“kann” / “kann verzichtet werden”)17. Negative recommendations use the same grades.

24. How are conflicts of interest handled?

All participants declare their interests, which are then rated for relevance to the guideline topic. Under the Regelwerk, a low relevant conflict means no leading role (such as coordinator or working-group lead); a moderate conflict means abstaining from votes on related recommendations; and a high conflict means exclusion from discussion and voting on the related topics17. The ratings and consequences are documented in the guideline report.

25. How long does an AWMF guideline remain valid?

A maximum of five years17. After that, the guideline must be updated to remain current.

26. What is a living guideline?

A guideline in which individual recommendations are updated as soon as relevant new evidence becomes available, so the unit of update is the recommendation rather than the whole guideline18. In the AWMF framework, living guidelines are updated at intervals of no more than 12 months17.

27. Which review types feed an S3 guideline?

S3 recommendations require a systematic evidence base, usually systematic reviews of each key question. Rapid reviews can be used if the approach is agreed with the guideline group and AWMF advisor, and every shortcut is reported as Cochrane rapid review guidance recommends16; scoping reviews are best used to refine key questions and rarely support graded recommendations on their own. This reflects common practice; the Regelwerk does not set rules on review type. Our AWMF S3 evidence review article explains the requirements in detail.

28. Where are the methods of an AWMF guideline documented?

In the guideline report (Leitlinienreport), which describes the evidence search and appraisal, the consensus process and conflict-of-interest management17.

Sources for this topic: AWMF-Regelwerk (version 2.2, 2025); Garritty 2024.

Pubrica team verdict

Most review-type questions come down to matching the method, checklist and registry to what the review is meant to answer.

Frequently asked questions

No. Both use systematic, transparent methods, but a scoping review maps the available evidence and concepts, whereas a systematic review answers a focused question and usually appraises and synthesises results1.

No. PROSPERO excludes scoping reviews; use OSF Registries, INPLASY or a published protocol instead810.

Not by relabelling it. A scoping review can be a useful precursor that confirms eligibility criteria and questions for a later systematic review1, but the systematic review needs its own protocol, structured with PRISMA-P14, and its own registration, for example in PROSPERO if it is eligible8. Cite the scoping review as the work that informed it.

Yes. An update is in development, but the 2018 checklist remains the version to report against until the new one is published57.

Yes. Scoping reviews can draw on evidence from any research methodology and on non-research sources such as policy documents2; state the types of evidence sources in your eligibility criteria and report each information source under PRISMA-ScR item 75.

S2k guidelines are based on structured consensus without a systematic evidence base; S3 guidelines combine a systematic evidence base with structured consensus17.

A maximum of five years; living guidelines are updated at intervals of no more than 12 months17.

A scoping review maps the extent and nature of evidence on a broad question1; a rapid review answers a focused question, usually about effectiveness, using streamlined systematic review methods so that decision-makers get results sooner16.

Sources

Sources were checked on 22 November 2026. Requirements and guidance may change after that date; confirm the current version with the issuing body.

  1. 1Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. Available from: https://doi.org/10.1186/s12874-018-0611-x
  2. 2Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119-26. Available from: https://doi.org/10.11124/JBIES-20-00167
  3. 3Pollock D, Peters MDJ, Tricco AC, Munn Z, Jia RM, Alexander L, et al. Scoping reviews (2026). In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis. JBI; 2024 [cited 2026 Nov 22]. Available from: https://doi.org/10.46658/JBIMES-24-09
  4. 4Pollock D, Peters MDJ, Khalil H, McInerney P, Alexander L, Tricco AC, et al. Recommendations for the extraction, analysis, and presentation of results in scoping reviews. JBI Evid Synth. 2023;21(3):520-32. Available from: https://doi.org/10.11124/JBIES-22-00123
  5. 5Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73. Available from: https://doi.org/10.7326/M18-0850
  6. 6Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Available from: https://doi.org/10.1136/bmj.n71
  7. 7Tricco AC, Robinson E, Straus SE, Colquhoun H, Godfrey CM, Moher D, et al. Updating the PRISMA reporting guideline for scoping reviews: a scoping review. J Clin Epidemiol. 2026;196:112314. Available from: https://doi.org/10.1016/j.jclinepi.2026.112314
  8. 8Centre for Reviews and Dissemination. PROSPERO: international prospective register of systematic reviews [Internet]. York: University of York; [cited 2026 Nov 22]. Available from: https://www.crd.york.ac.uk/prospero/
  9. 9Centre for Reviews and Dissemination. A new and improved PROSPERO website has been launched [Internet]. York: University of York; 2025 Mar 7 [cited 2026 Nov 22]. Available from: https://www.york.ac.uk/crd/news/2025/prosperoupdate/
  10. 10van den Akker OR, Peters GY, Bakker CJ, Carlsson R, Coles NA, Corker KS, et al. Increasing the transparency of systematic reviews: presenting a generalized registration form. Syst Rev. 2023;12(1):170. Available from: https://doi.org/10.1186/s13643-023-02281-7
  11. 11Center for Open Science. Registration and preregistration FAQs [Internet]. OSF Support; [cited 2026 Nov 22]. Available from: https://help.osf.io/category/549-registration-and-preregistration-faqs
  12. 12Canellas JVDS, Ritto FG, Rodolico A, Aguglia E, Fernandes GVO, Figueredo CMDS, et al. The international platform of registered systematic review and meta-analysis protocols (INPLASY) at 3 years: an analysis of 4,658 registered protocols on inplasy.com, platform features, and website statistics. Front Res Metr Anal. 2023;8:1135853. Available from: https://doi.org/10.3389/frma.2023.1135853
  13. 13Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, et al. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953-68. Available from: https://doi.org/10.11124/JBIES-21-00242
  14. 14Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. Available from: https://doi.org/10.1186/2046-4053-4-1
  15. 15Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2. Available from: https://doi.org/10.1186/2046-4053-1-2
  16. 16Garritty C, Hamel C, Trivella M, Gartlehner G, Nussbaumer-Streit B, Devane D, et al. Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness. BMJ. 2024;384:e076335. Available from: https://doi.org/10.1136/bmj-2023-076335
  17. 17Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) – Ständige Kommission Leitlinien. AWMF-Regelwerk „Leitlinien“. Version 2.2. Berlin: AWMF; 2025. Available from: https://www.awmf.org/regelwerk/
  18. 18Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ; Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47-53. Available from: https://doi.org/10.1016/j.jclinepi.2017.08.009

scoping reviewPCC frameworkdata chartingPRISMA-ScROSF registrationINPLASY

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation, so check its guide if it has one.

Dr. Charlie. (2026, November 22). Review Types and Protocols Q&A: Scoping Reviews, PRISMA-ScR, Protocol Registration and AWMF Guidelines. Pubrica. https://pubrica.com/academy/qa/scoping-review-prisma-scr-registration-awmf-questions-and-answers/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.